Add PSILOCYBE.md

PSILOCYBE.md

@@ -0,0 +1,618 @@
+# The Fifth Kingdom at Home: A Cultivation Science Guide to Psilocybin-Containing Fungi
+
+*A scientifically grounded, beginner-accessible guide to the biology, chemistry, ecology, and cultivation of Psilocybe cubensis and related tryptamine-producing species.*
+
+---
+
+> **Legal Disclaimer**
+> Psilocybin and psilocin are Schedule I controlled substances under United States federal law and are similarly restricted in most jurisdictions worldwide. The legal status of these compounds is changing rapidly — readers are solely responsible for understanding and complying with the laws of their specific jurisdiction before undertaking any activity described in this guide. Nothing in this document constitutes legal advice.
+>
+> **Grove5 Disclaimer**
+> The information in this guide is provided for educational and scientific purposes only. Grove5 does not condone the cultivation, manufacture, possession, or use of psilocybin or any controlled substance in jurisdictions where such activities are prohibited by law. Grove5's products and resources are intended for lawful use only.
+>
+> **Informational Disclaimer**
+> This guide is a scientific and cultivation reference. It is not a consumption guide, a dosing guide, or medical advice. The pharmacological and clinical information presented reflects the peer-reviewed literature as of the date of writing. The regulatory landscape surrounding psilocybin is evolving at an unprecedented pace — specific legal details described herein may be outdated by the time you read them. Readers seeking current legal status in their jurisdiction should consult primary legal sources or organizations tracking psychedelic policy in real time.
+
+---
+
+## Prologue: A stolen pathway
+
+The story of psilocybin does not begin with Timothy Leary or R. Gordon Wasson or Albert Hofmann. It does not begin with the Mazatec healers of Oaxaca, though they are essential to it. It begins, if we follow the molecular evidence backward far enough, with a theft.
+
+Somewhere in the forests of the ancient world — perhaps 65 million years ago, perhaps more recently — a fungus acquired a set of four genes from another organism. Not through sex, not through inheritance, but through **horizontal gene transfer**: the same mechanism bacteria use to swap antibiotic resistance across lineages, applied here to a cluster of enzymes capable of synthesizing one of the most pharmacologically remarkable molecules ever to appear in a living cell. The cluster spread. It jumped species boundaries with a promiscuity that has no analogue in the biology of plants or animals. Today it sits in the genomes of fungi from at least seven distantly related genera — *Psilocybe*, *Panaeolus*, *Gymnopilus*, *Pluteus*, *Inocybe*, *Pholiotina*, *Conocybe* — lineages so far apart on the fungal family tree that their last common ancestor predates the dinosaurs.[^1]
+
+The molecule those four enzymes produce is **psilocybin**. The story of why any fungus makes it remains, at the level of adaptive function, genuinely unsettled. The story of what it does to a vertebrate nervous system has, in the last decade, become one of the most intensely studied questions in neuroscience and psychiatry. And the story of how to cultivate the fungi that make it is, at its core, the same story as the rest of this guide series — an act of biological collaboration with an organism that has spent millions of years developing its own agenda in ecosystems we are just beginning to understand.
+
+This guide covers four species in depth: *Psilocybe cubensis*, the widely cultivated tropical dung-lover that has become the world's most grown psychoactive fungus; *P. tampanensis*, producer of the remarkable underground sclerotia called Philosopher's Stones; *P. cyanescens*, the cold-loving wood-chip species of the temperate Pacific Northwest and urban parks of Europe; and *Panaeolus cyanescens*, a distantly related dung-loving tropical whose alkaloid ratio tells a different chemical story. Along the way it covers the biology of over 165 related *Psilocybe* species, the complete biosynthetic machinery of the psilocybin pathway, the dual-mechanism pharmacology that has made psilocybin the subject of serious clinical trials, and the honest truth about what we know and don't know about cultivation "strains."
+
+The science here is real. The wonder is warranted. And the legal and practical context is inescapable — please read the disclaimers above before proceeding.
+
+---
+
+## 1. A kingdom of chemical thieves: the genus Psilocybe and its relatives
+
+### Where Psilocybe sits in the fungal tree
+
+*Psilocybe* is a genus of agarics — gilled mushrooms — placed in the order **Agaricales**, family **Hymenogastraceae**. It took mycologists until the molecular era to sort out where it actually belongs, because the little brown mushrooms that make up most of its approximately 165 species don't look dramatically different from the little brown mushrooms in hundreds of other genera. Spore color, gill attachment, veil remnants, and habitat are useful but insufficient for drawing clear lines.
+
+The critical taxonomic event came when chemists noticed that some *Psilocybe* species blue distinctively when bruised — and that others, formerly lumped in the same genus, don't. Molecular phylogenetics confirmed what the chemistry implied: the bluing species form a coherent, monophyletic clade united by the presence of the psilocybin biosynthetic cluster, while the non-bluing species scattered across a separate lineage now called **Deconica**. The formal split, enacted by Redhead, Moncalvo, Vilgalys, Matheny, Guzmán and Redhead in 2007 and subsequently accepted by the Nomenclature Committee for Fungi, reserved the name *Psilocybe* for the psilocybin-containing clade and moved the remainder to *Deconica* in family Strophariaceae.[^2]
+
+The most recent phylogenomic treatment, by Bradshaw, Dentinger and colleagues (2024, *PNAS* 121:e2311245121), sampled 2,983 single-copy gene families across 71 herbarium specimens and dated the *Psilocybe* crown at approximately 56 million years old — deep in the Eocene, when the forests that would become our temperate and tropical woodlands were beginning their modern character. Two ancient clades diverge within the genus: one predominantly wood-associated, one predominantly dung-associated, with the dung-associated clade including *P. cubensis* and a pair of independent transitions onto large-herbivore manure. The implication is striking: the ancestors of your grow jar were probably already living on dinosaur dung.
+
+### The full landscape of psilocybin-containing fungi
+
+*Psilocybe* is not alone in making psilocybin. The Frontiers 2022 review by Strauss et al. catalogs confirmed psilocybin production across:
+
+**Psilocybe** (~165 species, ~144 with the bluing reaction): the center of gravity. Species range from the Arctic to the tropics, on every substrate from cattle dung to pine needles to rotting alder roots. The type species, *P. semilanceata* — the Liberty Cap — fruits in upland pastures across Europe and is probably the most foraged wild psilocybin mushroom in the world.
+
+**Panaeolus / Copelandia** (~13 psychoactive species in family Bolbitiaceae): a completely separate evolutionary lineage, mostly dung-loving, tropical. The star is *P. cyanescens*, which has a distinctive alkaloid profile we'll address in Chapter 8.
+
+**Gymnopilus** (~14 species in family Strophariaceae): large, rusty-orange wood-rotting mushrooms. *G. luteofolius* and *G. junonius* ("Spectacular Rustgill") contain psilocybin, though potency is variable and bitterness discourages most foragers.
+
+**Pluteus** (family Pluteaceae, order Agaricales but a completely different lineage): *P. salicinus* and *P. nigroviridis* contain psilocybin and baeocystin in small amounts; primarily a natural history curiosity.
+
+**Inocybe** (family Inocybaceae): at least three species contain aeruginascin and related compounds. Crucially, the 2025 paper by Schäfer, Haun, Rupp & Hoffmeister demonstrated that *Inocybe* uses *dissimilar enzymes* to produce its tryptamine compounds — convergent evolution, not the same cluster. **Inocybe species are also dangerously toxic** due to muscarinic alkaloids; they should never be foraged.
+
+**Pholiotina cyanopus** and **Conocybe cyanopus**: small, fragile dung-loving species; aeruginascin producers. *Pholiotina/Conocybe* are notoriously difficult to identify and grow alongside deadly species; they are not cultivation candidates.
+
+The total count of confirmed or probable psilocybin-containing species, across all genera, sits somewhere between 200 and 250. The number is growing as molecular tools make tropical collections more tractable.
+
+### The horizontal gene transfer story
+
+This is one of the most startling findings in modern mycology, and it deserves its full due.
+
+In most organisms, the genes for biosynthesizing a particular molecule are scattered across the genome and inherited vertically — down through generations, from parent to offspring. Fungi are unusual in that their secondary metabolite genes are often clustered together in tight genomic neighborhoods, with all the enzymes for a pathway encoded within a few kilobases of each other. These clusters can, under certain circumstances, move between species as a unit — transferred not through reproduction but through direct DNA uptake, viral vectors, or parasitic elements. The phenomenon is called **horizontal gene transfer** (HGT), and it is well-characterized in bacteria (it's how antibiotic resistance spreads across species) but rarer and more surprising in eukaryotes.
+
+Reynolds, Vijayakumar, Gluck-Thaler, Korotkin, Matheny & Slot (2018, *Evolution Letters* 2:88–101) recovered the psilocybin biosynthetic cluster from *Psilocybe cubensis*, *Panaeolus cyanescens* and *Gymnopilus dilepis* — three fungi separated by hundreds of millions of years of evolution, placed in entirely different families. They found that the phylogenies of the cluster genes were radically incongruent with the species tree: the cluster sequences grouped together regardless of which species they came from, exactly as you would expect if the cluster had spread as a unit between lineages rather than being inherited from a single common ancestor. The most parsimonious explanation is HGT — and the ecological pattern is suggestive of mechanism: all the psilocybin-producing lineages are concentrated in **dung and late-stage-wood-decay niches**, environments where fungi are packed together with mycophagous insects and nematodes in ways that create both opportunity for gene exchange and selection pressure for chemical defenses.[^3]
+
+The more recent 2025 finding by Schäfer and colleagues in *Inocybe* complicates this picture slightly: those species use structurally different enzymes, suggesting at least some tryptamine biosynthesis in fungi is genuinely convergent rather than transferred. The full history of psilocybin's evolution is still being written, but the dominant story is clear: this pathway did not appear once and radiate through the fungal tree. It was, in some meaningful sense, invented and then shared.
+
+### Why does the fungus make it?
+
+The honest answer is: we don't fully know.
+
+The leading hypothesis is **chemical defense against mycophagous invertebrates** — insects and fly larvae that eat mushrooms. This is supported by the distribution of psilocybin-producing lineages in dung and decaying wood, both substrates heavily colonized by invertebrates, and by the fact that serotonin 5-HT receptors — the pharmacological targets of psilocybin's active metabolite psilocin — are ancient and conserved: flies, beetles, and nematodes have them too.
+
+But the 2019 "zombie cicada" paper by Boyce, Gluck-Thaler, Slot, Stajich, Davis, James, Cooley, Panaccione and colleagues (*Fungal Ecology* 41:147–164) added a troubling complication: they found psilocybin in *Massospora* fungi, insect pathogens that live inside cicadas and manipulate their behavior to maximize fungal spore dispersal. In *Massospora*, psilocybin is not deterring an insect — it is *controlling* one. The molecule's neuroactive properties appear to be the functional constant across these different ecological contexts; whether it deterred, sedated, or reprogrammed the insects it encountered may have shifted with context.[^4]
+
+Laboratory assays showing that *Drosophila* larvae thrive on *P. cubensis* tissue (Meyer & Slot 2023, *Fungal Genetics and Biology* 167:103812) further complicate the simple deterrence story. Psilocybin's ecological function may be more like the rest of secondary metabolism — a chemical broadcasting system whose meaning is context-dependent and still being deciphered.
+
+### Conservation
+
+*Psilocybe cubensis* and *P. semilanceata* are common and globally distributed; there is no conservation concern for the species as a whole. However, the IUCN Global Fungal Red List Initiative has preliminary **Endangered** assessments for several Mexican endemic *Psilocybe* species — *P. aztecorum*, *P. fagicola*, *P. banderillensis*, *P. mammillata*, *P. neoxalapensis* and *P. cordispora* — whose cloud-forest habitat is projected to contract by ~68% under current climate models. Thirty-three *Psilocybe* species are protected under Mexico's NOM-059-SEMARNAT-2010 environmental law. The principle that applies in this guide series holds here too: cultivation is the appropriate way to engage with this genus. The wild populations that remain, particularly the high-altitude Mexican species intertwined with Indigenous ceremonial practice going back centuries, are not yours to harvest.
+
+---
+
+## 2. The four enzymes: psilocybin biosynthesis in depth
+
+In 2017, Janis Fricke, Felix Blei and Dirk Hoffmeister published a paper in *Angewandte Chemie International Edition* (56:12352–12355) that changed the field. They heterologously expressed all four enzymes of the psilocybin biosynthetic pathway in isolation, ran them in sequence with their substrates, and watched psilocybin assemble itself from L-tryptophan in a test tube. For the first time, the complete enzymatic logic of one of the most pharmacologically significant natural products in biology was laid out step by step.
+
+What they found was four enzymes, four reactions, one product — and an elegant chemical logic that has since been exploited by bioengineers to produce psilocybin in bacteria, yeast, and cell-free systems at scales that would have been unimaginable a decade ago.
+
+### L-tryptophan: the starting material
+
+Everything begins with **L-tryptophan**, one of the twenty canonical amino acids, synthesized in the fungus's own cytoplasm from the shikimate pathway. Tryptophan carries an indole ring — a bicyclic aromatic system fused from a benzene and a pyrrole ring — which is the chemical scaffold on which all tryptamine chemistry is built. The indole ring is what gives all these compounds their structural family resemblance, and what ultimately determines their biological activity: it is the shape that fits serotonin receptors.
+
+### Step 1: PsiD — decarboxylation
+
+**PsiD** is a **tryptophan decarboxylase** — a flavin-independent enzyme that removes the carboxyl group from the amino acid side chain, converting L-tryptophan to **tryptamine**. This is the same reaction that produces tryptamine in plants (where it is the precursor to indole alkaloids like strychnine) and in some bacteria. Fricke et al. describe PsiD as "a new class of fungal L-tryptophan decarboxylases" — its protein sequence is distinct from plant tryptophan decarboxylases, suggesting independent evolution of the same catalytic function. PsiD also accepts 4-hydroxy-L-tryptophan as a substrate, providing an alternative entry point to the pathway.
+
+The product, **tryptamine**, is itself pharmacologically active — it is a trace amine that binds some receptors at high concentrations — but it has essentially no psilocybin-like effects. The magic is not yet present. Four more bonds need to be formed.
+
+### Step 2: PsiH — hydroxylation
+
+**PsiH** is a **cytochrome P450 monooxygenase** — a member of the vast and ancient P450 superfamily, which uses a heme iron center and molecular oxygen to hydroxylate otherwise inert C–H bonds. PsiH adds a hydroxyl group at the **4-position** of the indole ring, converting tryptamine to **4-hydroxytryptamine**. This is the rate-limiting step of the pathway, requiring NADPH and oxygen, and PsiH was the most technically difficult enzyme to express in the Fricke experiments.
+
+The 4-position hydroxylation is everything. The resulting 4-OH tryptamine is structurally similar to serotonin (5-hydroxytryptamine) — the placement of a hydroxyl group on the indole ring is what creates the pharmacological resemblance to the brain's own neurotransmitter. The *position* of that hydroxyl — 4, not 5 — is what makes the pharmacology different. At the 4-position, the hydroxyl is on the top face of the indole ring, pointing in a different direction than serotonin's 5-OH group; this geometry is what allows psilocin to partially mimic serotonin at its receptor while being pharmacologically distinct.[^5]
+
+### Step 3: PsiK — phosphorylation
+
+**PsiK** is an **ATP-dependent kinase** that phosphorylates the 4-hydroxyl group of 4-hydroxytryptamine, converting it to **norbaeocystin** (4-phosphoryloxytryptamine, bearing a primary amine). This step uses ATP as the phosphate donor and produces ADP as a byproduct. The phosphorylation accomplishes something chemically unremarkable but biologically essential: it converts a reactive, oxidation-prone phenol into a stable phosphate ester. The resulting molecule, norbaeocystin, is water-soluble, stable, and — crucially — essentially inactive pharmacologically. The phosphate group is too large and too charged to let norbaeocystin cross the blood-brain barrier.
+
+The phosphate group also makes norbaeocystin a prodrug — a form that can be stored safely inside the fungal cell and then rapidly converted to an active form when needed. This is the same logic as psilocybin itself: the mushroom is, in a chemical sense, storing loaded neuropharmacological ammunition in stabilized form until something triggers its release.
+
+### Step 4: PsiM — double methylation
+
+**PsiM** is an **S-adenosyl-L-methionine (SAM)-dependent N-methyltransferase** that performs two successive methylations on the primary amine of norbaeocystin. The first methylation converts norbaeocystin to **baeocystin** (the mono-N-methyl product). The second converts baeocystin to **psilocybin** (the di-N-methyl product, 4-phosphoryloxy-N,N-dimethyltryptamine). SAM donates a methyl group in each reaction and is converted to S-adenosylhomocysteine. PsiM cannot perform a third methylation — which is why the N,N,N-trimethyl analog aeruginascin is not made by *Psilocybe* and requires a different enzyme (in *Inocybe* and *Pholiotina*).
+
+The dimethylation matters enormously for pharmacology. The N,N-dimethyl group makes psilocin (psilocybin's active form after dephosphorylation) more lipophilic than serotonin, improving its ability to cross cell membranes and the blood-brain barrier. It also changes the binding geometry at 5-HT receptors in ways that shift selectivity and signaling.
+
+### The complete pathway, summarized
+
+| Step | Enzyme | Reaction | Substrate → Product |
+|---|---|---|---|
+| 1 | PsiD | Decarboxylation | L-tryptophan → tryptamine |
+| 2 | PsiH | 4-hydroxylation | Tryptamine → 4-hydroxytryptamine |
+| 3 | PsiK | Phosphorylation | 4-hydroxytryptamine → norbaeocystin |
+| 4a | PsiM | N-methylation (×1) | Norbaeocystin → baeocystin |
+| 4b | PsiM | N-methylation (×2) | Baeocystin → **psilocybin** |
+
+### PsiR and PsiT: the cluster's supporting cast
+
+Flanking the four core enzymes in the psilocybin gene cluster are two additional genes: **PsiT1** and **PsiT2** (major facilitator superfamily efflux transporters) and **PsiR** (originally annotated as a helix-loop-helix transcriptional regulator). PsiT1 and PsiT2 are presumed to export psilocybin out of the producing hyphae — a self-resistance mechanism that keeps the reactive intermediate from accumulating to toxic levels inside the cell. PsiR's regulatory role is less certain; Bradshaw et al. (2018) noted that PsiR is also present in some non-psilocybin-producing fungi, suggesting it may not be specifically dedicated to regulating this pathway.
+
+### The tryptamine family: baeocystin, norbaeocystin, aeruginascin, norpsilocin
+
+Because PsiM adds methyl groups iteratively, psilocybin is never the only tryptamine in a mature mushroom. The biosynthetic intermediates accumulate to varying degrees:
+
+**Norbaeocystin** (primary amine phosphate): the PsiK product, typically present at low concentrations. Pharmacologically: fails to produce psychedelic effects in standard rodent assays (Glatfelter et al. 2022), likely because the primary amine is too protonated at physiological pH to cross the blood-brain barrier.
+
+**Baeocystin** (secondary amine phosphate, the N-monomethyl analog of psilocybin): more abundant than norbaeocystin in most species. Dephosphorylated to **norpsilocin** (4-hydroxy-N-methyltryptamine) in vivo. Norpsilocin is a near-full agonist at 5-HT2A in vitro, but also fails to produce the rodent head-twitch response — possibly because rapid MAO degradation prevents sufficient brain penetration.
+
+**Aeruginascin** (N,N,N-trimethyl-4-phosphoryloxytryptamine, a quaternary ammonium compound): found in *Inocybe aeruginascens*, *Pholiotina cyanopus*, and some collections of *P. cyanescens*. Its dephosphorylated form, **4-HO-TMT**, has affinity for 5-HT2A and 5-HT2B. Aeruginascin may be associated with the "wood-lover's paralysis" syndrome described in Chapter 9.
+
+**The entourage effect hypothesis** — that these co-occurring tryptamines synergize with psilocybin to produce effects qualitatively different from pure compound — is plausible and widely discussed but not experimentally confirmed. No controlled clinical comparison of pure psilocybin versus whole-mushroom extract has been published. Glatfelter et al.'s 2022 data argue against the strong version: individually, none of the minor tryptamines produce psychedelic effects. Whether they modulate or prolong psilocin's action through MAO competition or pharmacokinetic effects remains an open question.[^6]
+
+### Where the compounds concentrate
+
+Gotvaldová, Hájková, Borovička, Jurok, Cihlářová & Kuchař (2021, *Drug Test. Anal.* 13:439–446) analyzed *P. cubensis* tissue systematically by UHPLC-MS:
+
+- **Caps**: ~1.03% total tryptamines by dry weight
+- **Stipes**: ~0.52% total tryptamines — roughly half the cap concentration, though within-fruit variation was high enough that this difference was not statistically significant
+- **Mycelium**: detectable psilocin only (~0.47%), essentially no psilocybin — consistent with mycelium lacking the full PsiM activity needed for double methylation, or rapidly dephosphorylating whatever psilocybin forms
+- **Spores**: no detectable tryptamines
+
+The practical implications: caps are more potent than stipes by roughly 2:1 on average, but the variance within a single grow is so high that other factors — developmental stage, substrate, drying technique — dominate.
+
+### Post-harvest stability
+
+The Gotvaldová (2021) stability data are the most important practical chemistry finding in the cultivation literature:
+
+- **Dry mushrooms stored in the dark at room temperature** degraded the slowest: ~30% loss over 15 months.
+- **Powder in ambient conditions** degraded fastest — the milling destroys cell compartmentalization and accelerates enzymatic contact between psilocybin and PsiP/PsiL.
+- **Freezing whole fresh mushrooms** caused the worst acute degradation: ice crystal rupture flooded psilocin-containing cells with the phosphatase and laccase that turn it blue and degrade it.
+- **Heat above 100 °C** degrades phosphorylated tryptamines while transiently increasing psilocin (dephosphorylation outpaces oxidation at moderate temperatures), but sustained heat above ~120 °C degrades both.
+
+The cultivation message is direct: thorough drying to below 5% residual moisture, in the dark, at room temperature, is the most effective preservation method. Desiccant (food-grade silica gel) over 24–48 hours achieves this. Powder for immediate use, whole mushrooms for long-term storage.[^7]
+
+---
+
+## 3. What psilocybin does: the pharmacology
+
+This chapter is not a consumption guide. It is the science underlying one of the most significant pharmacological stories of the early 21st century — a story that has moved from counterculture to clinical trial to executive order in two decades, and whose mechanistic foundation is now understood well enough to explain not just what psilocybin does but how, at the level of receptor binding and neural circuitry.
+
+### Psilocybin is a prodrug
+
+When you eat a mushroom, you consume **psilocybin** — the phosphorylated, water-soluble, pharmacologically inactive form. Within minutes of reaching the small intestine, alkaline phosphatase in the gut wall cleaves the phosphate group, releasing **psilocin** (4-hydroxy-N,N-dimethyltryptamine). Psilocin is absorbed into the bloodstream, where its lipophilicity allows it to cross the blood-brain barrier readily. Peak plasma psilocin is reached approximately 80–105 minutes after oral ingestion; half-life is ~2–3 hours; effects persist 4–8 hours as psilocin is gradually glucuronidated and excreted. The phosphorylation strategy — storing the active compound as an inactive prodrug — is the fungus's own invention, and it has been adopted by pharmaceutical chemists designing synthetic psilocybin precisely because it provides stability and water-solubility that would otherwise require formulation chemistry.
+
+### Mechanism 1: 5-HT2A partial agonism
+
+Psilocin's primary acute-effects mechanism is **partial agonism at serotonin 5-HT2A receptors**. This was established by the classic ketanserin blocking experiments (Vollenweider et al. 1998, *NeuroReport*; replicated Preller et al. 2017) and confirmed in the definitive human PET imaging study: Madsen, Fisher, Burmester and colleagues (2019, *Neuropsychopharmacology* 44:1328–1334) gave healthy volunteers oral psilocybin (3–30 mg) and measured cortical 5-HT2A receptor occupancy using the radioligand [¹¹C]Cimbi-36. Occupancies up to 72% correlated directly with plasma psilocin concentration and with subjective intensity. The dose-occupancy-effect relationship is clean: more psilocin → more 5-HT2A occupancy → stronger experience.[^8]
+
+"Partial agonism" means psilocin recruits approximately 50–80% of the maximal G-protein signaling response that full agonists like serotonin produce — it activates the receptor without activating it completely. This partial activation, combined with biased agonism (psilocin preferentially coupling to certain intracellular signaling pathways over others), likely underlies the specific character of the psilocybin experience as distinct from other 5-HT2A drugs. The 5-HT2A receptors most relevant to psychedelic effects are the ones on **layer 5 pyramidal neurons** of the prefrontal cortex — large, heavily connected cells that are central to the brain's integration of sensory, cognitive, and self-referential information.
+
+### The default mode network and REBUS
+
+Since Carhart-Harris et al.'s 2012 *PNAS* paper (using 2 mg iv psilocybin in 15 subjects), fMRI studies have consistently shown that psilocin produces:
+
+- **Reduced functional connectivity within the default mode network** (DMN) — the brain's resting-state network associated with self-referential thought, mind-wandering, and the "narrative self"
+- **Increased between-network connectivity** — the brain's normally segregated functional networks become more globally integrated
+- **Increased signal entropy** — brain activity becomes less predictable, more variable, more exploratory
+
+Carhart-Harris & Friston synthesized these observations into the **REBUS** model (*Relaxed Beliefs Under pSychedelics*, and the "anarchic brain hypothesis"), published in *Pharmacological Reviews* (2019, 71:316–344). Under hierarchical predictive coding — the theoretical framework in which the brain constantly generates predictions about the world and updates them with sensory evidence — high-level regions maintain beliefs about self and reality with strong "precision weights" that suppress bottom-up revision. Psilocin, acting at layer-5 pyramidal neurons, relaxes those precision weights: the brain's priors become more flexible, bottom-up sensory information gets more say, and the usually rigid architecture of self-perception temporarily dissolves. This is not mysticism. It is a neurocomputational account of why psychedelic-assisted therapy can loosen deeply entrenched cognitive patterns — the rigid pessimism of depression, the fixed behavioral loops of addiction — in a way that weeks of conventional therapy sometimes cannot.[^9]
+
+### Mechanism 2: TrkB direct binding
+
+In 2023, two companion papers in *Nature Neuroscience* transformed the mechanistic picture. Moliner, Girych, Brunello, Kovaleva, Biojone, Enkavi and colleagues (2023, *Nat. Neurosci.* 26:1032–1041) showed that psilocin (and LSD) bind directly to **TrkB** — the receptor for brain-derived neurotrophic factor (BDNF) — with affinities approximately 1,000-fold higher than conventional antidepressants like imipramine. The companion paper (Bhatt et al., *Nat. Neurosci.* 26:1023–1031) showed that these drugs' effects on neurotrophic signaling, plasticity, and antidepressant-like behavior in mice depended on TrkB binding and BDNF signaling — but were independent of 5-HT2A.[^10]
+
+The mechanistic separation is clean: **5-HT2A → acute perceptual effects; TrkB-BDNF → antidepressant neuroplasticity.** This explains the apparent disconnect between psychedelic intensity and therapeutic outcome — non-hallucinogenic doses of psilocybin can produce antidepressant effects in animal models, consistent with TrkB acting at concentrations below those needed for 5-HT2A-mediated hallucinations.
+
+The structural basis: psilocin fits into a transmembrane pocket on TrkB that is normally occupied by cholesterol. When psilocin displaces cholesterol, TrkB dimerizes more readily and is more efficiently activated by BDNF. It is, in essence, a **potentiator of the brain's own growth-factor signaling** — and it does this with a binding affinity that dwarfs every antidepressant currently on the market.
+
+### Neuroplasticity at the synapse
+
+Shao, Liao, Gregg, Davoudian, Savalia, Delagarza & Kwan (2021, *Neuron* 109:2535–2544) used chronic two-photon microscopy to track 1,820 individual dendritic spines on layer-5 pyramidal neurons in living mouse medial frontal cortex before and after a single psilocybin dose (1 mg/kg). Within 24 hours, spine density had increased by ~10% and spine size had grown; at one month, both measures remained elevated. Electrophysiology confirmed increased miniature excitatory postsynaptic current frequency — more synaptic connections, firing more often. A single dose had restructured the brain's cortical circuitry in ways that persisted for weeks.
+
+This is why the clinical researchers talk about psilocybin "opening a window of plasticity" — a period after the acute experience during which the brain is unusually receptive to learning new patterns of thought and behavior. It is why the therapeutic sessions that follow the psilocybin experience — integration, psychotherapy, support — appear to matter as much as the compound itself.
+
+### Clinical evidence
+
+The headline trials establish psilocybin as a serious therapeutic candidate:
+
+**Treatment-resistant depression:** Carhart-Harris, Giribaldi, Watts and colleagues (2021, *NEJM* 384:1402–1411) compared two 25 mg psilocybin doses with six weeks of escitalopram (a standard SSRI) in 59 patients with moderate-to-severe MDD. The primary outcome was not significantly different between arms — psilocybin was non-inferior to a well-established antidepressant in a 6-week comparison. The larger Compass Pathways COMP360 phase 2b trial (Goodwin et al. 2022, *NEJM* 387:1637–1648) tested a single 25 mg psilocybin dose in 233 patients with treatment-resistant depression and found a significant 6.6-point greater MADRS reduction at week 3 versus the 1 mg control dose; 37% of the 25 mg group met response criteria at 3 weeks, declining to 20% at 12 weeks. Most participants experienced adverse events.
+
+**Alcohol use disorder:** Bogenschutz et al. (2022, *JAMA Psychiatry*) reported that two psilocybin sessions plus therapy reduced heavy drinking days by 83% versus 51% in the placebo-therapy group at 8 months — the largest effect size reported for any pharmacological treatment of alcohol use disorder.
+
+**Tobacco cessation:** Johnson et al. (Johns Hopkins, 2014/2017 open-label) found 80% verified abstinence at 6 months after 2–3 psilocybin sessions plus cognitive behavioral therapy, compared to ~35% for the best available pharmacotherapy.
+
+### Safety
+
+Physiologically, psilocybin has an extraordinary safety profile. There is no known lethal human dose; the rat LD50 (~280 mg/kg) implies a human equivalent of roughly 40 times a typical 25 mg therapeutic dose. The primary physiological effects are mild transient increases in heart rate and blood pressure. The 5-HT2B agonist activity of psilocin raises theoretical valvulopathy concerns with chronic high-frequency use, but this is not relevant to single therapeutic sessions.
+
+The real risks are psychological and contextual: psychedelic experiences can be profoundly disorienting, occasionally terrifying, and can unmask latent psychiatric vulnerabilities. **Hard contraindications** include personal or family history of psychosis or bipolar I disorder (risk of precipitating a manic or psychotic episode); concurrent serotonergic medications including SSRIs, SNRIs, and particularly MAOIs (serotonin syndrome risk and pharmacokinetic interactions); and active severe cardiovascular disease. The consistent finding across clinical trials is that with appropriate screening, preparation, and support, adverse outcomes are rare and manageable — but those conditions are not incidental to safety. They are the safety.[^11]
+
+---
+
+## 4. The bluing reaction: an oxidation story
+
+Pick up a fresh *Psilocybe cubensis* fruit body and bend the stipe. Watch the tissue at the stress point. Within a few seconds, white flesh turns dusty blue-green. Within minutes, the blue deepens. The color does not fade.
+
+This is one of the most visually distinctive features of psilocybin-containing fungi, the field identification cue that foragers and cultivators rely on, and one of the most chemically interesting reactions in the mushroom kingdom. It is also widely misunderstood: the common belief that bluer means more potent is not supported by the chemistry. What bluing actually indicates is that psilocin has been released from cells and begun to degrade.
+
+### The enzymatic cascade
+
+When mushroom tissue is damaged — cut, bruised, pressed, or aged — two enzymes that are normally compartmentalized become active on psilocybin. **PsiP**, a phosphatase, cleaves the phosphate group from psilocybin to produce **psilocin** (4-hydroxy-N,N-dimethyltryptamine). **PsiL**, a laccase (a multicopper oxidase like the laccases we met in the oyster guide), then oxidizes psilocin's 4-OH group, abstracting electrons and generating a reactive psilocin radical.
+
+Lenz, Sherwood, Hoffmeister and colleagues (2020, *Angew. Chem. Int. Ed.* 59:1450–1454) traced what happens to that radical in detail. The psilocin radical undergoes **oxidative dimerization** — two radical molecules couple together — and the coupled products undergo further oxidation and rearrangement to produce a family of indoloquinoid oligomers. The dominant early product, characterized by MALDI-MS and NMR in the Lenz et al. 2021 follow-up (*Chem. Eur. J.* 27:14096), is a **7,7′-coupled quinoid psilocyl dimer** that absorbs visible light at wavelengths corresponding to blue-green. As the reaction continues and larger oligomers accumulate, the color deepens. This is a heterogeneous mixture of chromophores, not a single blue compound.[^12]
+
+### What bluing tells you — and doesn't
+
+**Bluing confirms psilocin was present.** A mushroom that blues contains or contained psilocin (the dephosphorylated, active form). This is a reliable positive indicator.
+
+**Bluing intensity is not a reliable potency indicator.** The intensity of bluing depends on the amount of psilocin (not psilocybin) present, on the activity of PsiL laccase (which varies by strain, age, and conditions), and on oxygen availability. A mushroom with high psilocybin but low laccase activity may blue minimally. A mushroom that has already partially degraded its psilocin — and is therefore less potent — may blue intensely.
+
+**Heavy bluing in stored mushrooms indicates degradation.** Blue or blue-green powder, or mushrooms that blue dramatically on their own in storage without being touched, have undergone psilocin oxidation and their potency has decreased accordingly. Thoroughly dried, dark-stored mushrooms should show minimal bluing — the drying process reduces cell-disrupting water activity, and darkness prevents photodegradation.
+
+---
+---END---
+
+## 5. Psilocybe cubensis — biology and natural history
+
+*Psilocybe cubensis* (Earle) Singer, 1949. Common names: Cubes, Golden Teachers, Magic Mushrooms, Hongos (Mexico), Teonanácatl (Nahuatl, historically applied to several species).
+
+It is a medium-sized, caramel-to-gold-capped mushroom with a white partial veil, purple-black spore print, and white gills that darken as spores mature. The stipe is white, thickening toward the base, with a persistent annulus (veil remnant) that stains purple-black with falling spores. Cap diameter runs 1.5–8 cm in the wild; cultivated specimens push larger. None of this morphology is remarkable — it is, in the field guide sense, a nondescript little brown mushroom wearing a veil. What makes it remarkable is entirely inside.
+
+### Taxonomy and discovery
+
+Franklin Sumner Earle first described this species in 1906 from a cattle pasture in Cuba, naming it *Stropharia cubensis*. Patouillard independently described it from Tonkin (now Vietnam) in 1907; Murrill collected Florida specimens in 1941 and called them *Stropharia cyanescens*. Rolf Singer transferred the species to *Psilocybe* in 1949. The species had been formally described, lost, redescribed, and redescribed again before anyone understood why it was interesting.
+
+The closest free-living relative of cultivated *P. cubensis* was discovered in Africa in 2025 (Bradshaw et al., *Proceedings of the Royal Society B* 293:20252270), suggesting the domesticated lineage may trace its origins to an African or pantropical ancestor — a reminder that the organism's evolutionary history is messier and more interesting than its taxonomic address.[^13]
+
+### Natural ecology: the dung specialist
+
+*P. cubensis* is **coprophilous** — dung-loving — preferring the manure of large domesticated herbivores, especially cattle (*Bos taurus*) and water buffalo (*Bubalus bubalis*). Native range: tropical and subtropical Americas (Gulf Coast USA, Mexico, Central America, Cuba, northern South America), with naturalized populations across Southeast Asia, India, Australia, and southern Africa wherever cattle ranching spread.
+
+Why dung? The bovine rumen pre-digests lignocellulosic plant material through a dense microbial community, producing manure that is a pre-processed substrate of partially degraded plant fiber, microbial biomass, organic acids, and minerals. Fresh cattle dung has a C:N ratio of roughly 20–25:1, near-optimal for many basidiomycetes. It holds moisture, buffers pH near neutral, and arrives in tropical pastures in quantities that renew themselves constantly.
+
+Wild *P. cubensis* fruiting follows the rain — 1–4 weeks after significant rainfall events at surface temperatures of 22–28 °C. A typical flush develops in 3–7 days from first visible primordia to full maturity.
+
+### Mycelium and spores
+
+*P. cubensis* mycelium is white to off-white, initially tomentose (fluffy), developing **rhizomorphic** (rope-like, strand-forming) character as colonization progresses. Rhizomorphic strands radiating through substrate are associated with more vigorous colonization and reliable pinning. Metabolite exudate — amber to rust-colored droplets — is normal and common; these are iron-chelating siderophores, not contamination. A faint sweet-earthy smell is characteristic.
+
+Basidiospores are dark purple-brown to nearly black, 11.5–17 × 8–11 µm, with a germ pore. They contain no detectable psilocybin or psilocin (Gotvaldová 2021) — pharmacologically inert. This is legally significant: spores not containing a scheduled substance are not federally controlled in most US jurisdictions, though California, Georgia, and Idaho explicitly ban spore possession.
+
+---
+
+## 6. Cultivating *Psilocybe cubensis*
+
+### The colonization phase
+
+Colonization of *P. cubensis* is the easiest step — the species is an aggressive competitor on grain and dung-based substrates. The challenge is sterile technique, not biology.
+
+#### Substrate science
+
+**PF Tek: the original method.** Robert "Psilocybe Fanaticus" McPherson published the Brown Rice Flour and Vermiculite Technique in 1992. The standard mix — 2 parts vermiculite : 1 part brown rice flour : roughly 1 part water — remains the beginner standard because it is forgiving and requires only half-pint mason jars and a home pressure cooker.
+
+Brown rice flour supplies starch, protein (~7% N), and B-vitamins at sufficient nutrient density for colonization and fruiting without overwhelming contamination resistance. Vermiculite absorbs 3–4× its dry weight in water, creating the field-capacity moisture the mycelium needs, while providing no nutrition to competitors. The dry vermiculite cap layer placed over the moist mix before sterilization is a mechanical filter — a needle can penetrate it without contaminating the nutritious layer below.
+
+**Field capacity** is the key moisture concept across all cultivation: a substrate at field capacity holds maximum water without dripping when squeezed firmly. Below it, hyphal turgor collapses. Above it, pore spaces flood and anaerobic bacteria win.
+
+**Grain spawn** is the professional standard beyond PF Tek: rye berries, wheat, oats, popcorn, or milo are soaked overnight, simmered to ~30% moisture, drained, surface-dried, and pressure-sterilized at 15 PSI for 90 minutes. The overnight soak — identical to oyster grain preparation — allows dormant *Bacillus* endospores to germinate and become heat-killable. Skipping this step is the single most common cause of bacterial wet rot.
+
+**Bulk substrates.** Colonized grain spawn is crumbled into bulk substrate for final colonization and fruiting:
+
+| Substrate | Description | Notes |
+|---|---|---|
+| **CVG** (coco coir + vermiculite + gypsum) | 650 g coir : 1.4 L vermiculite : 100 g gypsum | Pasteurized; reliable, accessible, forgiving |
+| **Pasteurized manure** | Horse or cattle manure ± coir | Closest to native ecology; highest yields; more contamination risk |
+| **Straw** | Wheat or oat straw, pasteurized | Lower yields than CVG or manure |
+| **Master's Mix** | 50% hardwood + 50% soy hulls | Excellent for oysters/Hericium; sub-optimal for cubensis |
+
+CVG is the current community standard. Unlike grain, bulk substrate is pasteurized (65–75 °C for 60–90 minutes) rather than sterilized, preserving a microbial community that competes against *Trichoderma*.
+
+**Casing layers.** A 1–2 cm casing of moist peat-vermiculite over fully colonized bulk maintains surface humidity, harbors *Pseudomonas* and other bacteria producing pinning-trigger volatiles, and recreates the soil-air interface of natural dung habitat. pH adjusted to 7.5–8 suppresses *Trichoderma* and favors pinning.[^14]
+
+**Supplementation.** Adding nitrogen-rich materials increases yield modestly but disproportionately raises contamination risk. *P. cubensis* does not require high nitrogen — its native substrate is already nitrogen-rich — and excess supplementation primarily feeds competitors. Alkaloid content is essentially independent of substrate nitrogen enrichment in available data.
+
+#### Parameters to hold during colonization
+
+| Parameter | Target | Why |
+|---|---|---|
+| **Temperature** | 24–28 °C / 75–82 °F | Optimum enzyme kinetics; above 30 °C Trichoderma and Bacillus gain decisive advantage |
+| **CO₂** | High tolerated; sealed containers fine | Vegetative cubensis tolerates 5,000–20,000 ppm without pinning |
+| **Light** | Dark is fine | No light requirement during colonization |
+| **Moisture** | Field capacity | Below: hyphal collapse; above: anaerobic bacteria |
+| **Time** | 10–18 days grain; 14–21 days bulk | Faster with liquid culture; slower from spore syringe |
+
+#### Contamination — the specific threats
+
+**Trichoderma** (green molds, especially *T. harzianum*): starts as white sectors indistinguishable from cubensis, turns lime-green within 4–7 days. Once visible: bag and remove without opening. Spores are airborne and will contaminate adjacent grows.
+
+**Cobweb mold** (*Cladobotryum dendroides*): gray-white, fast-spreading, feathery surface growth. Unlike Trichoderma, can often be treated in early stages — it dries back with reduced humidity. Key distinction: cobweb flattens against the substrate when blown on; healthy mycelium stands up.
+
+**Bacterial blotch** (*Pseudomonas tolaasii*): yellow-brown slimy patches on developing fruit bodies. Prevented by adequate FAE.
+
+**Bacterial wet rot** (*Bacillus* spp.): sour or ammonia smell from grain; *Bacillus* endospores surviving inadequate sterilization. Prevented by the overnight soak protocol.
+
+### The fruiting phase
+
+*P. cubensis* is a forgiving fruiter relative to *Pleurotus* and especially relative to *Hericium*. The temperature drop requirement is modest, CO₂ sensitivity manageable, and the species pins under a wide range of conditions.
+
+#### Pinning triggers
+
+**Fresh air exchange (FAE)** is the dominant signal. When CO₂ drops below roughly 1,000–1,500 ppm after the sealed colonization environment is opened, pinning is triggered. This is why the simplest method works: open the jar, place the colonized cake in a humid enclosure with airflow, and wait.
+
+**Humidity**: 85–95% RH at the substrate surface. Lower humidity causes pin abortion. Shotgun fruiting chambers (SGFC) — perforated plastic storage bins with a damp perlite layer — maintain adequate RH through the "fan and mist" protocol.
+
+**Light**: diffuse ambient light at any intensity is sufficient. *P. cubensis* uses light to orient fruit body development, not as a pinning trigger per se.
+
+**Temperature drop**: 2–4 °C from colonization temperature is helpful but not strictly required — unlike *Pleurotus ostreatus* (10–15 °C shock) or *Hericium* (6–12 °C shock). Many growers fruit cubensis at colonization temperature with reliable results.
+
+#### The primordium developmental sequence
+
+Hyphal knots (dense hyphae aggregates at the substrate surface) → primordia (white domes, 1–3 mm) → pins (miniature fruit bodies with discernible cap and stipe) → mature fruit bodies. Pins inflate over 5–10 days. The **partial veil** — thin membrane connecting cap edge to upper stipe — stretches as the cap expands and eventually tears. Veil break initiates sporulation and is the timing event cultivators watch for.
+
+Elevated CO₂ during fruiting produces elongated, thin, poorly-capped fruit bodies. At 1,000–2,000 ppm: visibly stretched stipes. Above 3,000 ppm: morphology noticeably compromised. Standard FAE (fanning 2–4× daily) is sufficient for home grows.
+
+### Harvest
+
+#### Timing: the veil
+
+Optimal harvest is **just before veil break** — when the veil is stretched thin and taut, cap edges beginning to upturn, but the membrane still intact. Reasons: maximum biomass before the energy cost of spore release; reduced spore contamination of the grow chamber (spore rain vectors bacterial blotch and is a respiratory irritant); tryptamine concentration at or near peak in the cap.
+
+Harvest by gripping the stipe at the base and twisting while pulling — takes the entire fruit body, leaving no stump. Leaving stipe stubs invites bacterial colonization.
+
+#### Multi-flush behavior
+
+A healthy bulk substrate produces 2–4 flushes spaced 5–10 days apart. Typical distribution: flush 1 ≈ 50–60% of total yield; flush 2 ≈ 25–30%; flush 3 ≈ 10–15%. Initiate subsequent flushes by rehydrating the substrate — dunking in cool water for 4–12 hours or heavy misting — and resetting the fruiting environment. After three flushes, rising contamination pressure and falling yield make further cycling uneconomical.
+
+#### Drying
+
+The Gotvaldová (2021) stability data are decisive: cracker-dry mushrooms stored in the dark at room temperature degrade substantially more slowly than any other storage condition.
+
+1. Initial drying: food dehydrator at 35–40 °C with maximum airflow, or wire rack in front of a fan, for 4–8 hours until externally dry
+2. Final drying: airtight container over food-grade silica gel desiccant for 24–48 hours until the mushroom snaps cleanly ("cracker dry")
+3. Storage: airtight, dark, room temperature. Whole mushrooms degrade significantly more slowly than powder. Never freeze fresh whole mushrooms — ice crystal disruption catastrophically accelerates the PsiP/PsiL degradation cascade.[^7]
+
+---
+
+## 7. The strain question: an honest reckoning
+
+There are, at this writing, hundreds of named *Psilocybe cubensis* "strains" circulating in the cultivation community. Golden Teacher. Penis Envy. Tidal Wave. B+. Albino A+. Cambodian. There are regional names and breeder names and names that are obvious marketing. There are crosses of crosses of crosses whose breeding history is entirely oral tradition.
+
+Here is what the science actually says.
+
+### What we know
+
+**Genetic diversity is real.** The McKernan, Kane, Crawford, Chin, Trippe & McLaughlin (2021, *F1000Research* 10:281) PacBio HiFi assembly of the "Penis Envy" isolate produced a 46.6 Mb genome across 32 contigs, with the full psilocybin biosynthetic cluster on a single 3.2 Mb contig. When Illumina data from a second isolate was aligned to this reference, a SNP appeared every ~243 bases — genuine genetic diversity exists. Strains are not genetically identical.
+
+**Potency differences between named strains are real but highly variable.** The Oakland Hyphae **Psilocybin Cup** (now Hyphae Cup), analyzed by HPLC at Hyphae Labs, is the largest community-science potency dataset. Across >170 *P. cubensis* submissions:
+
+- **Golden Teacher** average: ~0.75% total tryptamines (range ~0.5–1.0%)
+- **Penis Envy** average: ~2.0–2.9% total tryptamines
+- **Tidal Wave "Enigma" (2021 winner)**: **3.82% total tryptamines** (2.26% psilocybin + 1.56% psilocin)
+- Range across all submissions: 600–24,600 µg psilocybin per gram — a **40-fold range**
+- Within a single flush from a single block: ~100% potency variation between individual mushrooms
+
+### What we don't know
+
+**No peer-reviewed analytical study has compared named cubensis strains under controlled conditions with replicates.** The Hyphae Cup data is community-science: no controlled substrate, drying protocol, or replicate testing. It establishes that wide variation exists; it does not identify the cause.
+
+**Most named strains lack voucher specimens.** Without a physical, sequenced, herbarium-deposited sample, a "strain" is a name attached to a cultural lineage that cannot be verified or compared to other collections bearing the same name.
+
+**The polyploidy claims for Penis Envy are unconfirmed.** The widely circulated belief that PE is tetraploid (proposed to explain larger fruit bodies and higher alkaloid content) is inconsistent with the McKernan 2021 genome, which is consistent with normal diploidy.
+
+**Strain names are not genetically stable.** "Golden Teacher" from five vendors may represent five genetically distinct isolates. Decades of undocumented propagation, oral-tradition naming, and informal exchange mean the relationship between a name and a genotype is unreliable without sequencing.
+
+### The honest synthesis
+
+Strains exist as real genetic entities with phenotypic differences in average size, color, growth rate, and alkaloid concentration. The *penis envy* phenotype — compact, dense, thick-stiped, high-psilocybin — appears genuinely heritable. The 40-fold potency range in the Hyphae Cup data is real.
+
+But individual variation within a strain — driven by substrate, developmental stage at harvest, and drying protocol — is comparable in magnitude to the average difference between strains. Your growing and drying technique probably matters more than your genetics. Treat potency claims for named strains without controlled analytical data as community belief, not measurement.[^15]
+
+---
+
+## 8. The advanced species: four different chemical stories
+
+### 8.1 Psilocybe tampanensis — The Philosopher's Stones
+
+*Psilocybe tampanensis* Guzmán & Pollock, 1978. Common names: Philosopher's Stones, Magic Truffles.
+
+The discovery story is inseparable from tragedy. In 1977, pharmacologist Steven Pollock found an unusual *Psilocybe* in a sandy field near Tampa, Florida — the only wild collection of *P. tampanensis* known until a second Mississippi collection in 2016. He co-described it with Gastón Guzmán in 1978. In 1981, Pollock was murdered in his San Antonio laboratory. The DEA subsequently destroyed his cultures and ten pounds of cultivated sclerotia. A single surviving culture shared before his death has produced essentially every cultivated *P. tampanensis* in existence. All Philosopher's Stone cultures trace their lineage to that one collection.[^16]
+
+**The sclerotium.** Under nutrient or moisture stress, *P. tampanensis* mycelium aggregates into **sclerotia**: dense, hardened, brownish-black masses of pseudoparenchymatous tissue evolved as dormant survival structures analogous to plant tubers. They store glycogen and trehalose; in nature they allow the mycelium to survive drought or fire.
+
+Sclerotia contain psilocybin at ~0.31–0.68% by dry weight, with minimal psilocin — the phosphorylated prodrug form predominates because PsiP phosphatase activity is suppressed in the dense, low-water-activity sclerotial tissue. This means sclerotia blue weakly when cut, and their psilocybin is substantially more stable than fruit body psilocin.
+
+**Cultivation.** Rather than introducing fruiting-trigger conditions (cool temperature, FAE, humidity), you *withhold* them. Colonized grain is kept sealed at colonization temperature (24–26 °C) with no humidity boost and no temperature drop. Over 3–12 weeks the mycelium begins forming sclerotia in the lower substrate layers. When no new growth is visible, harvest: crumble the block and separate the sclerotia.
+
+**The Dutch legal exploit.** The 2008 Netherlands ban on psilocybin mushrooms targeted above-ground fruit bodies. Sclerotia — underground mycelial masses — escaped the statutory language. Today, "magic truffles" are sold legally as regulated, taxed products in Dutch smart shops. This is an accident of legislative specificity, not a principled biological distinction.
+
+| Parameter | Range |
+|---|---|
+| Colonization temperature | 24–26 °C |
+| Colonization environment | Sealed throughout; no fruiting triggers |
+| Sclerotia formation | Same temperature, no drop, no humidity boost |
+| Substrate | Rye grain spawn; rye straw also used |
+| Time to harvest | 3–12 weeks post-colonization |
+| Psilocybin content | ~0.31–0.68% dry weight |
+
+---
+
+### 8.2 Psilocybe cyanescens — The Wavy Caps
+
+*Psilocybe cyanescens* Wakefield ex Brodie & Hora, 1960. Common names: Wavy Caps, Cyan Mushrooms, "Cyans."
+
+Wavy Caps are the ghost species of the urban forest. They appear in autumn in the wood-chip mulch beds of parks, botanical gardens, and university campuses — arriving without announcement, fruiting briefly in enormous numbers (UK patches of 100,000+ fruit bodies have been documented), and vanishing before most people register what they've seen. Their native range appears to be the Pacific Northwest, but the commercial wood-chip mulch trade has spread them across Europe, New Zealand, and parts of Asia so thoroughly that "native" is nearly meaningless for this species.
+
+**A critical safety note.** *Galerina marginata* — the Deadly Galerina, containing amatoxins — grows in similar habitats at similar times of year with similar LBM appearance. Differences: *Galerina* has a rusty-brown spore print (not purple-brown), does not blue, has a more persistent membranous ring, and typically smells mealy. Misidentification has caused deaths. When in doubt, it is not *P. cyanescens*.
+
+**Ecology and substrate.** *P. cyanescens* is **lignicolous** — a wood-decay species. It is not a dung species, not a meadow species. It eats wood chips. The reason cubensis cultivation techniques do not transfer here is fundamental: its enzyme system is oriented toward lignocellulose, not starch and simple sugars. Grain-to-CVG methods fail.
+
+**Potency.** Approximately 0.66% psilocybin and 0.60% psilocin by dry weight (Stamets 1996) — roughly 1.5–2× typical *P. cubensis* — with high baeocystin. Total tryptamines ~1.0–1.5% dry weight.
+
+**Cultivation.** Outdoor wood-chip beds are the standard and most reliable approach: 15–30 cm deep hardwood chip beds (alder, oak, maple, beech — not pine or cedar, whose aromatic oils inhibit colonization), inoculated with grain spawn at 10–15% by volume through the bottom two-thirds. Colonization proceeds invisibly over summer. **Cold shock of 8–15 °C triggers pinning** — in temperate climates this happens naturally in late September/October. Beds fruit October through January and, crucially, **fruit perennially for years** with no re-inoculation, making this the most efficient long-term cultivation approach for the species.
+
+| Parameter | Range |
+|---|---|
+| Substrate | Hardwood wood chips (alder, oak, beech, maple preferred) |
+| Colonization temperature | 15–24 °C |
+| Fruiting temperature | 7–18 °C — cold required |
+| Cold shock | 8–15 °C drop, or natural seasonal autumn drop |
+| Outdoor fruiting season | October–January (temperate Northern Hemisphere) |
+| Total tryptamines | ~1.0–1.5% dry weight |
+| Cultivation difficulty | Very easy outdoors; difficult indoors |
+
+---
+
+### 8.3 Psilocybe azurescens — Azure Caps
+
+*Psilocybe azurescens* Stamets & Gartz, 1995. Common names: Flying Saucers, Azure Caps, "A's."
+
+In 1979, a group of Boy Scouts allegedly encountered unusual, intensely bluing mushrooms while camping near the Columbia River estuary near Astoria, Oregon. Word eventually reached Paul Stamets, who formally described the species with Jochen Gartz in 1995, naming it after his son Azureus. The type locality remains the coastal dunes and alder riparian zones of the northern Oregon coast.
+
+**Extreme potency.** Approximately 1.8% psilocybin, 0.5% psilocin, 0.4% baeocystin by dry weight — total tryptamines of roughly 2.7%, or approximately 3–4× average *P. cubensis*. *P. azurescens* is among the most chemically potent psilocybin-containing fungi ever measured. A small mushroom is not a small dose.
+
+**Ecology.** Lignicolous, coastal, cold-tolerant. Native to the Pacific Northwest coast, growing in dune grasses (*Ammophila*), coastal alder, and hardwood debris. Fruiting season: September through January, with frost tolerance exceeding every other cultivated psilocybin species. The broadly convex cap with a distinctive low central umbo, wavy margin, and extreme bluing are the most reliable field characters.
+
+**Cultivation.** Like *P. cyanescens*, a wood-chip specialist that cannot be reliably cultivated indoors. Outdoor hardwood chip beds inoculated in summer, colonizing invisibly through autumn, fruit reliably once soil temperatures drop below ~15 °C. More cold-adapted than *P. cyanescens* — it prefers the coldest end of the temperature range.
+
+**Wood-lover's paralysis.** A syndrome of temporary muscular weakness — sometimes extending to transient loss of coordination lasting several hours — has been reported after consuming *P. azurescens* and other lignicolous *Psilocybe* species. The 2025 Dörner et al. *Toxicon* paper provides the first systematic clinical toxidrome description. The leading proposed mechanism is aeruginascin or its dephosphorylated form 4-HO-TMT, possibly acting at peripheral 5-HT2B receptors. The mechanism is genuinely unresolved. Cultivators and foragers of lignicolous species should be aware of this risk.[^17]
+
+| Parameter | Range |
+|---|---|
+| Substrate | Hardwood wood chips; coastal alder preferred |
+| Fruiting temperature | 4–15 °C — cold required |
+| Fruiting season | September–January |
+| Total tryptamines | ~2.5–3.0% dry weight |
+| Wood-lover's paralysis risk | Present; mechanism unconfirmed |
+| Cultivation difficulty | Very easy outdoors in appropriate coastal climate |
+
+---
+
+### 8.4 Panaeolus cyanescens — The Blue Meanie
+
+*Panaeolus cyanescens* (Berk. & Broome) Sacc., 1887. Also known as *Copelandia cyanescens*. Common names: Blue Meanies, Pan Cyans, Copelandia.
+
+*Panaeolus cyanescens* is not a *Psilocybe*. Placed in family **Bolbitiaceae** (order Agaricales), it is a completely separate evolutionary lineage whose last common ancestor with *Psilocybe* predates the Cretaceous-Paleogene boundary. It almost certainly acquired the psilocybin biosynthetic pathway by horizontal gene transfer. The genetic and ecological context is entirely different — but experienced cultivators return to it for a specific reason: the alkaloid ratio.
+
+**The alkaloid ratio.** In most *P. cubensis*, psilocybin predominates over psilocin by roughly 4:1 to 8:1 in properly dried material. In *Panaeolus cyanescens*, Stijve's 1992 survey of 70 collections found an average of ~0.48% psilocin and only ~0.11% psilocybin — plus serotonin (~0.072%), baeocystin (~0.02%), and notably **urea (~1.8%)**. The species is psilocin-dominant.
+
+Psilocin does not require gut dephosphorylation before crossing the blood-brain barrier — it begins acting more immediately than psilocybin. In qualitative accounts, consumers describe faster onset, shorter duration (~4–6 hours versus cubensis's 6–8), and a more intensely visual character. Whether these differences are truly pharmacological or confounded by dose imprecision is not clinically established.
+
+The urea content is unusual in the fungal kingdom. Some researchers propose it serves as a cryoprotectant or osmoprotectant consistent with a tropical dung species navigating alternating wet and dry seasons.
+
+**Ecology.** Pantropical: Hawaii, Southeast Asia, India, Australia, Caribbean, Mexico. Coprophilous on cattle and water buffalo dung. Fruit bodies small (cap 1.5–4 cm), gray to brownish, dramatically and rapidly bluing when handled — consistent with high psilocin and active laccase. Spore print dark purple-brown to black.
+
+**Cultivation.** Warmer and more fastidious than *P. cubensis*: composted livestock manure substrate at 28–32 °C colonization temperature; fruiting at 24–30 °C; 90–95% humidity. The warm, humid, manure-based environment is also optimal for bacterial and mold competitors. Yields by weight are modest given small fruit body size. This species rewards experienced cultivators with clean technique and the means to sustain tropical conditions; it punishes beginners with contamination and abort-heavy flushes.
+
+| Parameter | Range |
+|---|---|
+| Mycelium temperature | 28–32 °C |
+| Fruiting temperature | 24–30 °C |
+| Substrate | Composted manure + coco coir |
+| Alkaloid profile | Psilocin-dominant (~0.48% psilocin, ~0.11% psilocybin) |
+| Onset relative to cubensis | Faster — no dephosphorylation lag |
+| Cultivation difficulty | Exacting; experienced cultivators only |
+
+---
+
+## 9. Sidebar: the wider genus and cousins worth knowing
+
+*Psilocybe semilanceata* (Liberty Cap): the most widely foraged wild psilocybin mushroom in Europe, fruiting in upland sheep pastures and unimproved grassland from September to December. An acutely conical cap with a pronounced papilla, ochraceous-brown when moist. Potency approximately equivalent to *P. cubensis*. Not cultivatable by standard indoor methods. Do not confuse with *Inocybe* or *Galerina* species in similar grassland habitats.
+
+*Psilocybe mexicana*: the species Roger Heim described from Mazatec *teonanácatl* ceremonies in 1957 and Albert Hofmann used to first isolate psilocybin and psilocin in 1958. Also produces sclerotia and is the primary truffle species alongside *P. tampanensis* in the Netherlands. Native to Mexican highland grasslands.
+
+*Psilocybe zapotecorum*: a large, potent Mexican species associated with sacred Zapotec ceremonial use, growing in riparian habitats and wet tropical forest understory. Not cultivated.
+
+*Gymnopilus junonius* (Spectacular Rustgill): a large, rusty-orange wood-rotting basidiomycete containing psilocybin and baeocystin in variable amounts. Often consumed accidentally by foragers; its extreme bitterness usually prevents dangerous overdose. Not cultivated and not a *Psilocybe*.
+
+**A standing note on *Inocybe*.** Several species contain aeruginascin and related tryptamines and appear in the HGT story. However, *Inocybe* species also contain muscarine and related cholinergic toxins and have caused human fatalities. They are not edible, not cultivatable, and should never be foraged as psilocybin sources.
+
+**Wood-lover's paralysis: the open question.** A syndrome of temporary muscular weakness — from rubbery legs to transient paralysis lasting several hours — has been reported with *P. cyanescens*, *P. azurescens*, and *P. allenii*. It is not consistently produced; many consumers of these species report no unusual effects. The 2025 Dörner et al. *Toxicon* paper is the first systematic clinical description. The aeruginascin / 4-HO-TMT hypothesis is plausible but unconfirmed. The practical message: lignicolous *Psilocybe* species carry a real risk that *P. cubensis* does not, and cultivators and foragers should be aware of it.
+
+---
+
+## 10. The legal and regulatory landscape: a snapshot
+
+This chapter exists with a structural caveat: the landscape is moving faster than any document can track. What follows is the framework as of May 2026 — use it to understand the architecture of the regulatory situation, not as a substitute for current jurisdiction-specific legal research.
+
+### US federal status
+
+Psilocybin and psilocin are separately listed as **Schedule I controlled substances** under the Controlled Substances Act of 1970 — the most restrictive federal classification. This has not changed. Cultivation of psilocybin-producing mushrooms is federal manufacture of a Schedule I substance.
+
+**Spore legality.** A DEA Drug & Chemical Evaluation Section letter (Boos, January 2024) confirmed that *Psilocybe* spores not yet containing psilocybin or psilocin are not federally scheduled. Spores become controlled at germination. Three states explicitly ban spore possession or sale: **California** (Health & Safety Code §11391), **Georgia** (Code §16-13-1), and **Idaho** (§37-2705(d)(35)). Florida's law is ambiguous; consult legal counsel.
+
+### The April 18, 2026 Executive Order
+
+President Trump signed *Accelerating Medical Treatments for Serious Mental Illness* on April 18, 2026 — the first executive-level endorsement of psychedelic medicine by a US administration. What it actually does:
+
+- Directs the FDA to issue **Commissioner's National Priority Vouchers** to psychedelic drugs with Breakthrough Therapy designation, potentially compressing approval from years to months
+- Directs FDA and DEA to establish a **Right-to-Try access pathway** for investigational psychedelic drugs
+- Allocates **$50 million through ARPA-H** to match state investments in psychedelic research
+- Directs the Attorney General to initiate DEA rescheduling reviews upon successful Phase 3 completion and FDA approval
+
+What it does **not** do: it does not reschedule psilocybin or psilocin — they remain Schedule I; it does not legalize cultivation, possession, or non-clinical use; it does not preempt state law. As Harvard Law's Petrie-Flom Center noted in April 2026: "presidents cannot compel rescheduling of a controlled substance." The EO establishes a pathway and signals political intent; legal rescheduling requires DEA action under statutory criteria.[^18]
+
+### State and local status
+
+**Oregon** (Measure 109, 2020): the first state-regulated psilocybin therapy program, operational since early 2023 through licensed Service Centers. Note: Measure 110 drug decriminalization was partially repealed by the legislature in 2024; Measure 109 services remain operational.
+
+**Colorado** (Proposition 122, 2022): decriminalized personal possession, home growing, and gifting (not sale) of psilocybin and related natural medicines for adults 21+. First licensed Healing Center (The Center Origin, Denver) received its license March 31, 2025.
+
+**City-level decriminalization** (enforcement deprioritization, not legalization): Denver (May 2019, first in US), Oakland, Santa Cruz, Washington DC, Ann Arbor, Detroit, Seattle, Somerville, Cambridge, Northampton MA, and a growing number of other municipalities.
+
+**International snapshot**: Netherlands (truffles/sclerotia legal and sold commercially; mushrooms banned 2008); Jamaica (psilocybin unscheduled and legal; active retreat industry); Brazil (psilocybin and psilocin not scheduled); Australia (rescheduled 2023 to permit prescription by authorized psychiatrists for treatment-resistant depression); UK (Class A, most restrictive); Canada (Schedule III; research exemptions and Special Access Program available).
+
+The standing caveat: this landscape is changing monthly. Consult current primary legal sources or organizations tracking psychedelic policy — Drug Policy Alliance, MAPS, Psymposia, Chacruna Institute — for jurisdiction-specific current status.
+
+---
+
+## 11. Conclusion: the molecule and the mushroom
+
+There is a fungus growing right now on a cattle pasture somewhere in subtropical America — a small, golden-capped thing emerging from dung in warm humid air, assembling four enzyme reactions into a molecule that will, if it reaches a primate brain, temporarily dissolve the boundaries between self and world. The mushroom doesn't know this. It is doing what its genome — partly assembled from horizontally transferred genes, partly inherited from ancestors who fruited on the dung of animals that haven't walked the earth for centuries — instructs it to do: reproduce.
+
+The molecule it makes crossed the blood-brain barrier of Mazatec healers for centuries before it crossed the blood-brain barrier of a Swiss chemist in 1958 and gave pharmacology a new problem to solve. Now it is in clinical trials. Now an executive order has been signed. Now PET scans show it occupying cortical serotonin receptors with dose-dependent precision, and two-photon microscopes have watched it grow new synapses in living mouse cortex and hold them for a month.
+
+And now there is this guide.
+
+The cultivation knowledge here is old and new simultaneously — old because humans have been growing *Psilocybe cubensis* on brown rice flour in mason jars since 1992, and new because the molecular machinery underlying every step from substrate to spore has only been characterized in the past decade. The science and the practice have been running in parallel without always knowing it, and closing that gap is what a guide like this is for.
+
+Grow with care, with full attention to the law that governs your jurisdiction, and with the humility appropriate to working with something this old and this strange. The fifth kingdom does not forgive carelessness, and neither does the legal system. But the biology — honestly followed — is one of the most remarkable things a curious person can put their hands into.
+
+Grow well.
+
+---
+
+# ENDNOTES
+
+[^1]: The horizontal gene transfer hypothesis was established by Reynolds, Vijayakumar, Gluck-Thaler, Korotkin, Matheny & Slot (2018, *Evolution Letters* 2:88–101; DOI 10.1002/evl3.42), who compared cluster gene phylogenies across *Psilocybe*, *Panaeolus*, and *Gymnopilus* and found them incongruent with species trees — the hallmark of HGT. The foundational framework for HGT of secondary metabolite gene clusters in fungi: Slot & Hibbett (2007, *PLoS One* 2:e1097). Full phylogenomics of *Psilocybe*: Bradshaw et al. (2024, *PNAS* 121:e2311245121). Psilocybin in *Massospora* (Ascomycota) confirming cross-phylum transfer: Boyce et al. (2019, *Fungal Ecology* 41:147–164). Dissimilar *Inocybe* enzymes suggesting convergent evolution: Schäfer, Haun, Rupp & Hoffmeister (2025, *Angew. Chem. Int. Ed.* e202512017). Species count (~165 psilocybin-producing *Psilocybe*): Strauss et al. (2022, *Frontiers in Forests and Global Change* 5:813998).
+
+[^2]: *Psilocybe* / *Deconica* split: Redhead, Moncalvo, Vilgalys, Matheny, Guzmán & Redhead (2007, *Persoonia* 22:127); accepted nomenclature by Norvell et al. (2010, *Mycotaxon* 111:480). Monophyly confirmed: Ramírez-Cruz, Guzmán, Villalobos-Arámbula, Rodríguez, Matheny, Sánchez-García & Guzmán-Dávalos (*Botany* 91:573–591, 2013). Type species: *P. semilanceata* (Fr.) P.Kumm., 1871.
+
+[^3]: Reynolds et al. (2018): cluster gene phylogenies incongruent with species tree, confirming HGT. Selfish operon model extended to fungi: Slot & Rokas (2011, *Curr. Biol.* 21:134). The ecological correlation — psilocybin clusters concentrated in dung and late-decay-wood habitats where mycophagous invertebrate pressure is high — is the functional argument for why the cluster confers fitness and why selection to maintain and transfer it is concentrated in these environments. Meyer & Slot (2023, *Fungal Genetics and Biology* 167:103812) provide the most comprehensive current review of ecological hypotheses.
+
+[^4]: Boyce et al. (2019, *Fungal Ecology* 41:147–164): psilocybin in *M. platypediae*/*M. levispora* (0.1–12.6 µg psilocin, 7.3–19.4 ng psilocybin per plug); cathinone in *M. cicadina* (44–300 ng/plug in 42% of plugs). The infected cicadas' continued mating behavior despite abdominal destruction disseminates spores — illustrating psilocybin functioning as a behavior modifier rather than a deterrent, the ecological role shifting with context.
+
+[^5]: Structural pharmacology of 4-OH vs. 5-OH: Cao et al. (2022, *Nat. Commun.* 13:6258) cryo-EM structure of psilocin at 5-HT2A; 4-OH makes hydrogen bonds with Ser242, Asn343 that serotonin's 5-OH does not contact. This underlies partial agonism — the different hydroxyl geometry produces different intracellular signaling efficiency. PsiH's cytochrome P450 chemistry is homologous to tryptophan 5-hydroxylase (rate-limiting serotonin biosynthesis enzyme) but produces a 4-hydroxy rather than 5-hydroxy product — the one enzymatic step that defines the structural difference between a neurotransmitter and a psychedelic.
+
+[^6]: Glatfelter, Partilla et al. (2022, *ACS Pharmacol. Transl. Sci.* 5:1580–1596): baeocystin, norbaeocystin, norpsilocin, aeruginascin, and 4-HO-TMT all fail to produce mouse head-twitch response in vivo. Proposed mechanisms: rapid MAO-A degradation (primary amines are MAO-A substrates; psilocin's dimethylamino group is protected) and limited CNS penetration. Aeruginascin is permanently charged as a quaternary ammonium and essentially unable to cross lipid bilayers. Aeruginascin review: Lenz et al. (2022, *ACS Pharmacol. Transl. Sci.*, PMC9568164). Authors state: "these data do not support psilocybin analogs as contributing to the psychedelic effects of *Psilocybe* mushrooms."
+
+[^7]: Gotvaldová, Hájková, Borovička, Jurok, Cihlářová & Kuchař (2021, *Drug Testing and Analysis* 13:439–446; PMID 33119971). Key findings: caps ~1.03% total tryptamines, stipes ~0.52%; mycelium psilocin only (~0.47%); spores undetectable. Stability ranking: dry/dark/room temperature degraded slowest (~30% loss over 15 months); frozen fresh degraded fastest (ice crystal disruption). Enzymatic basis: PsiP and PsiL are compartmentally separated from psilocybin in intact cells; disruption initiates the degradation cascade (Lenz et al. 2020, *Angew. Chem. Int. Ed.* 59:1450).
+
+[^8]: Madsen, Fisher, Burmester, Dyssegaard, Stenbæk, Kristiansen, Johansen, Lehel, Linnet, Svarer, Erritzoe, Ozenne & Knudsen (2019, *Neuropsychopharmacology* 44:1328–1334; PMID 30685771): eight subjects; [¹¹C]Cimbi-36 PET; cortical 5-HT2A occupancy up to 72%; sigmoidal dose-occupancy relationship; occupancy correlated with APZ altered-states score (r=0.86). Ketanserin blockade establishing 5-HT2A necessity: Vollenweider et al. (1998, *NeuroReport* 9:3897); replicated Preller et al. (2017, *Cereb. Cortex* 27:3207). Cryo-EM structure of psilocin at 5-HT2A: Cao et al. (2022, *Nat. Commun.* 13:6258).
+
+[^9]: Carhart-Harris, Erritzoe, Williams et al. (2012, *PNAS* 109:2138): reduced within-DMN functional connectivity correlated with subjective dissolution under 2 mg iv psilocybin. REBUS model: Carhart-Harris & Friston (2019, *Pharmacol. Rev.* 71:316–344). Predictive coding framework: Friston (2010, *Nat. Rev. Neurosci.* 11:127). Entropic brain: Carhart-Harris et al. (2014, *Front. Hum. Neurosci.* 8:20). The REBUS account provides a neurocomputational explanation for why integration therapy following psilocybin sessions matters: relaxed priors require active engagement with new learning to produce lasting change.
+
+[^10]: Moliner, Girych, Brunello, Kovaleva, Biojone, Enkavi et al. (2023, *Nat. Neurosci.* 26:1032–1041; DOI 10.1038/s41593-023-01316-5): TrkB transmembrane domain binding confirmed by molecular dynamics, cryo-EM, and point mutation; 1,000-fold affinity advantage over conventional antidepressants; neuroplasticity effects independent of 5-HT2A. Companion paper: Bhatt et al. (2023, *Nat. Neurosci.* 26:1023–1031; DOI 10.1038/s41593-023-01317-4). Dendritic spine growth: Shao, Liao, Gregg, Davoudian, Savalia, Delagarza & Kwan (2021, *Neuron* 109:2535–2544): single 1 mg/kg psilocybin dose, ~10% increase in spine density and size at 24 h, persistent at one month; elevated mEPSC frequency.
+
+[^11]: Clinical trials: Carhart-Harris, Giribaldi, Watts et al. (2021, *NEJM* 384:1402): psilocybin non-inferior to escitalopram in MDD (n=59, 6 weeks, primary outcome not significantly different). Goodwin, Aaronson, Alvarez et al. (2022, *NEJM* 387:1637): COMP360 phase 2b, 25 mg psilocybin produced 6.6-point greater MADRS reduction vs. 1 mg control at week 3; 37% response rate at week 3, 20% at week 12 (n=233). Alcohol use disorder: Bogenschutz et al. (2022, *JAMA Psychiatry*). Tobacco cessation: Johnson et al. (Johns Hopkins, 2014/2017); 80% biologically verified abstinence at 6 months. Safety review: Carhart-Harris & Goodwin (2017, *Neuropsychopharmacol.* 42:2105); Johnson, Richards & Griffiths (2008, *Psychopharmacol.* 197:433).
+
+[^12]: Bluing mechanism: Lenz, Sherwood, Kellner, Göhring, Hoffmeister (2020, *Angew. Chem. Int. Ed.* 59:1450–1454): PsiP dephosphorylates psilocybin to psilocin; PsiL laccase oxidizes psilocin to radical; radical undergoes oxidative dimerization. Chromophore characterization: Lenz et al. (2021, *Chem. Eur. J.* 27:14096–14105): 7,7′-coupled quinoid psilocyl dimer is dominant initial chromophore; larger oligomers deepen the color over time. The bluing intensity ≠ potency relationship is a direct consequence: bluing reflects psilocin (not psilocybin) exposure to laccase, not total alkaloid content.
+
+[^13]: Bovine rumen chemistry and coprophilous fungal succession: Richardson (1972, *Trans. Brit. Mycol. Soc.* 58:37); Bell (1983, *Dung Fungi*). Cattle dung C:N ratio (~20–25:1): USDA-NRCS Agricultural Waste Management literature. Closest free-living relative discovered in Africa: Bradshaw et al. (2025, *Proc. Royal Soc. B* 293:20252270) — suggesting the domesticated lineage may have spread globally with cattle agriculture rather than originating in the Caribbean as the type locality implies.
+
+[^14]: Casing microbiology in *Agaricus bisporus*: Rainey et al. (1990, *FEMS Microbiol. Ecol.* 73:227); Noble et al. (2009, *Fungal Biol.* 113:1206). *Pseudomonas putida* volatiles (1-octen-3-ol, dimethyl disulfide) trigger pinning in *A. bisporus*. Application to *P. cubensis* casing is inferred by analogy — no peer-reviewed mechanistic study of cubensis casing microbiology has been published. The pH 7.5–8 recommendation is empirically derived from commercial production experience; *Trichoderma* growth is maximally suppressed above pH 7.0 in published studies.
+
+[^15]: McKernan, Kane, Crawford, Chin, Trippe & McLaughlin (2021, *F1000Research* 10:281): open-access PacBio HiFi assembly; N50 3.3 Mb, 97.6% BUSCO, 46.6 Mb genome, 32 contigs. SNP density (~1 per 243 bases between isolates) confirms genuine intraspecific genetic diversity. Oakland Hyphae Psilocybin Cup 2021 results: published at oaklandhyphae.com; Tidal Wave Enigma 3.82% result confirmed by Hyphae Labs; 40-fold potency range across submissions. "Enigma" morphotype: albino, non-sporulating fruiting body variant found in multiple strains; its consistently elevated alkaloid content relative to normal-morphology variants in cup data is a documented observation without a mechanistic explanation in peer-reviewed literature.
+
+[^16]: Guzmán & Pollock (1978, *Mycotaxon* 7:377). Pollock's murder (January 1981) and DEA destruction of cultures: documented in Stamets (*Psilocybin Mushrooms of the World*, Ten Speed Press, 1996) and multiple mycological history accounts. Single-collection lineage of all cultivated *P. tampanensis*: community-documented, not formally verified by published molecular phylogenetics. Second wild collection (Mississippi, 2016): Alan Rockefeller, iNaturalist obs. ID 2697050. Sclerotial alkaloid content (0.31–0.68% psilocybin dry weight): Stamets & Gartz (1995) and Miraculix Lab analytical data.
+
+[^17]: *Psilocybe azurescens* description: Stamets & Gartz (1995, *Integration* 6:21–45); original alkaloid analysis in same paper. Wood-lover's paralysis first systematic clinical toxidrome description: Dörner, Zeymer, Tempel, Bartke, Rohrbach & Klinger (2025, *Toxicon*, PMID 40490153). Aeruginascin / 4-HO-TMT hypothesis: Christiansen & Fester (2019, *Psychedelic Science Review*); Lenz et al. (2022, structural analysis). The 5-HT2B peripheral mechanism is proposed by analogy to smooth muscle effects; direct experimental confirmation in the context of lignicolous *Psilocybe* consumption has not been published.
+
+[^18]: Trump EO *Accelerating Medical Treatments for Serious Mental Illness* (April 18, 2026): archived at whitehouse.gov/presidential-actions/2026/04/. Petrie-Flom Center legal analysis (Cohen & Marks, April 18, 2026): petrieflom.law.harvard.edu. Presidential rescheduling authority analysis: Mikos, "Can the President Reschedule Marijuana?" (2017, *Ohio State Law Journal* 78:1). FDA Priority Voucher issuances (Compass COMP360, Usona psilocybin, Transcend methylone): FDA Commissioner Makary, April 24, 2026. Colorado first licensed Healing Center: Colorado Public Radio, March 31, 2025. Australia TGA rescheduling: effective July 1, 2023.
+
+---
+
+*This guide draws on the foundational work of Gastón Guzmán, whose lifetime of systematic Psilocybe taxonomy gave the genus its scientific shape; Albert Hofmann, whose 1958 isolation of psilocybin and psilocin opened the pharmacology; Maria Sabina and the Mazatec healers whose ceremonial knowledge predates the laboratory by centuries and deserves acknowledgment in any honest telling of this story; Janis Fricke and Dirk Hoffmeister, whose 2017 biochemical characterization of the psilocybin biosynthetic pathway made the molecular story legible; Robin Carhart-Harris and colleagues at Imperial College London and UCSF whose clinical research rebuilt scientific credibility around psychedelic medicine; and the cultivation community — named and anonymous — whose collective empirical knowledge has never found its way into a peer-reviewed journal but built the practice that makes this guide possible.*